secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0000914475-23-000043
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q1 GAAP net loss $76.6M; INGREZZA sales $410M (+36% YoY)
-------------------------------------------------------------------

- INGREZZA net sales $410M, up 36% YoY; guidance reiterated at $1.67-1.77B for FY2023.
- GAAP net loss $76.6M ($0.79 loss per share) vs $13.9M income in Q1 2022.
- Non-GAAP net loss $49.5M ($0.51 loss per share) vs $29.7M income in prior year.
- Recorded $143.9M acquired IPR&D expense for Voyager gene therapy collaboration.
- Valbenazine PDUFA for Huntington chorea set for Aug 20, 2023; top-line data from crinecerfont expected early Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000043/0000914475-23-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000043/nbix-20230503.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer